Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients

Relapse after dose-reduced allograft in advanced myeloma patients remains high. To reduce the risk of relapse, we investigated a myeloablative toxicity-reduced allograft (aSCT) consisting of i.v. BU and CY followed by lenalidomide maintenance therapy in 33 patients with multiple myeloma (MM) who rel...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Bone marrow transplantation (Basingstoke) 2013-03, Vol.48 (3), p.403-407
Hauptverfasser: Kröger, N, Zabelina, T, Klyuchnikov, E, Kropff, M, Pflüger, K-H, Burchert, A, Stübig, T, Wolschke, C, Ayuk, F, Hildebrandt, Y, Bacher, U, Badbaran, A, Schilling, G, Hansen, T, Atanackovic, D, Zander, A R
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!